COA Lauds the Introduction of the Prescription Drug Price Transparency Act

Representative Doug Collins (R, Georgia) has proposed a bill that would increase the transparency of payment methodologies to pharmacies. The Prescription Drug Price Transparency Act (H.R. 1316) was introduced in the House of Representatives on March 2, with the intent of requiring pharmacy benefit managers (PBMs) to disclose their generic drug pricing information.

The Community Oncology Alliance (COA) offered its support for the bill and its co-sponsors. “If passed, the Prescription Drug Price Transparency Act, and other legislation like it, will finally help curb PBM abuses. Increasing PBM transparency and fees will also finally move our country closer to solving rising drug costs,” Ted Okon, executive director of COA, said in a statement.

Continue Reading on Targeted Oncology